Vera Therapeutics, Inc.

VERA · Nasdaq · United States

Share price · VERA

$25.58-6.70 (-20.76%) 3M

close as of 2026-11-18 · 24h delayed · vol 951K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VERA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 14 Aug 2026+9.5%
  2. 4 Aug 2026-7.1%
  3. 16 Jul 2026-8.0%
  4. 22 Jun 2026+9.5%
  5. 18 May 2026-8.0%

    Nothing announced by VERA that day or the session before.

  6. 13 May 2026+6.7%

    Nothing announced by VERA that day or the session before.

  7. 10 Apr 2026+10.0%

    Nothing announced by VERA that day or the session before.

  8. 19 Mar 2026+8.0%

    Nothing announced by VERA that day or the session before.

  9. 11 Mar 2026+4.4%

    Nothing announced by VERA that day or the session before.

Share of unusual movement by asset

For each asset, the share of VERA's own-move activity since 13 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
BLyS/APRIL (B-cell activating factor/a proliferation-inducing ligand)Protein / enzyme therapeutic
IgA Nephropathy

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
AtaciceptPhase 2pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Est. primary completion 2027-11 · NCT06983028 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
AtaciceptPhase 2IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Est. primary completion 2031-05-21 · NCT06674577 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$10M$41M$55M+ $329M short-term inv.$94M-$99M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$60M$49M+ $450M short-term inv.$109M-$100M operating cash flowreport ↗
2026-Q1—$86M$114M+ $482M short-term inv.$121M-$107M operating cash flowreport ↗
2025-Q3—$56M$58M+ $440M short-term inv.$80M-$62M operating cash flowreport ↗
2025-Q2—$58M$49M+ $508M short-term inv.$77M-$55M operating cash flowreport ↗
2025-Q1—$41M$55M+ $535M short-term inv.$52M-$54M operating cash flowreport ↗
2024-Q3—$40M$27M+ $326M short-term inv.$47M-$37M operating cash flowreport ↗
2024-Q2—$29M$25M+ $359M short-term inv.$34M-$25M operating cash flowreport ↗
2024-Q1—$23M$69M+ $335M short-term inv.$28M-$34M operating cash flowreport ↗
2023-Q3—$16M$27M+ $133M short-term inv.$20M-$23M operating cash flowreport ↗
2023-Q2—$16M$34M+ $147M short-term inv.$20M-$18M operating cash flowreport ↗
2023-Q1—$25M$138M+ $60M short-term inv.$30M-$26M operating cash flowreport ↗
2022-Q3—$20M$31M+ $84M short-term inv.$25M-$18M operating cash flowreport ↗
2022-Q2—$10M$51M+ $82M short-term inv.$15M-$19M operating cash flowreport ↗
2022-Q1—$13M$112M+ $39M short-term inv.$17M-$9.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$215M$355M+ $360M short-term inv.$75M-$241M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$126M$93M+ $548M short-term inv.$38M-$135M operating cash flowreport ↗
2023-FY—$78M$46M+ $115M short-term inv.$24M-$92M operating cash flowreport ↗
2022-FY—$69M$44M+ $71M short-term inv.$22M-$68M operating cash flowreport ↗
2021-FY—$22M$80M+ $0 short-term inv.$8.2M-$24M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($250K), 32 sales ($11.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-15Fordyce Marshall · director, PRESIDENT AND CEOOption exercise18,500$2.90$54KForm 4
2026-09-15Fordyce Marshall · director, PRESIDENT AND CEOOpen-market sale18,500$37.00$685KForm 4
2026-09-15Fordyce Marshall · director, PRESIDENT AND CEOOption exercise (derivative)18,500——Form 4
2026-09-11Young Joseph R · SVP, FINANCE, CHIEF ACCT OFFCROption exercise5,000$3.94$20KForm 4
2026-09-11Young Joseph R · SVP, FINANCE, CHIEF ACCT OFFCROption exercise (derivative)5,000——Form 4
2026-09-02Fordyce Marshall · director, PRESIDENT AND CEOOption exercise18,500$2.90$54KForm 4
2026-09-02Fordyce Marshall · director, PRESIDENT AND CEOOpen-market sale18,500$35.12$650KForm 4
2026-09-02Fordyce Marshall · director, PRESIDENT AND CEOOption exercise (derivative)18,500——Form 4